The growth capital will be used to expand BardyDx's sales force and monitoring services, advance research and development programs, and accelerate development of artificial intelligence diagnostic capabilities.
BardyDx is an innovator in digital health and remote patient monitoring, with a focus on providing diagnostically-accurate and patient-friendly cardiac patch and other monitors to the industry.
The company's Carnation Ambulatory Monitor (CAM) patch is a non-invasive, P-wave centric ambulatory cardiac monitor and arrhythmia detection device that is designed to improve patient compliance for men, women, and children through its lifestyle-enabling patch design.
SV Health Investors is a healthcare and life sciences venture capital and growth equity firm that targets early-stage opportunities in biotechnology; early-stage and revenue-stage opportunities in medical devices; and growth equity investments for later-stage businesses in healthcare services and digital health.
Health Enterprise Partners invests primarily in privately held, middle market companies in health care services and health care information technology.
The company seeks to invest in companies that improve the quality of the patient experience, expand access, and reduce the cost of health care.
Ascension Ventures is a strategic healthcare venture firm that constructs and manages a strategic portfolio of investments that deliver venture-level investment returns, have the potential to transform the healthcare industry, and significantly enhance the experience for patients, their families and their caregivers.
Fusion Antibodies signs GBP250,000 IP transfer deal with Finn Therapeutics
GSK's bepirovirsen accepted for review in China as potential Hepatitis B functional cure
4DMedical secures EU approval for CT:VQ as EUR83m funding fuels European expansion
Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences
Lunit and CellCarta partner to advance AI-driven digital pathology in CDx development
Nektar Therapeutics presents rezpegaldesleukin data at 2026 AAD Annual Meeting
Lilly presents Phase 3b Taltz (ixekizumab) plus Zepbound (tirzepatide) data at AAD Annual Meeting
AstraZeneca's tozorakimab meets primary endpoints in two Phase III COPD trials
Pharming receives positive CHMP opinion for Joenja marketing authorisation
Biocytogen partner NEOK Bio secures FDA IND clearance for cancer therapy candidate
Hoth Therapeutics deploys OpenClaw AI platform for drug discovery
Insilico Medicine and Tenacia expand AI-driven R&D collaboration